Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Features of Atrial Fibrillation in Patients with Arterial Hypertension and Extracardial Disorders

https://doi.org/10.20996/1819-6446-2019-15-3-368-373

Full Text:

Abstract

Aim. To study the features of the progression of atrial fibrillation (AF) in patients with arterial hypertension (HT) and comorbid extracardiac diseases.
Material and methods. In the observational cohort study 308 men 45-65 years old with AF and HT were observed Most patients also had the following comorbid extracardiac diseases: diabetes mellitus (DM; n=40), diffuse toxic goiter (DTG; n=42); hypothyroidism (HTH; n=59), abdominal obesity (AO; n=64), and chronic obstructive pulmonary disease (COPD; n=47). The comparison group consisted of 56 patients with AF and HT only. Clinical, anthropometric, laboratory parameters, levels of NT-proBNP and galectin-3, results of ECG, daily monitoring of ECG and blood pressure were
assessed initially and after 12 months.
Results. Persistent AF (29.6-65.2%) and long-term persistent AF (16-31.3%) were more common in groups with extracardiac diseases compared with the AF+HT group (20.4% and 14.2%, respectively). Permanent form of AF was statistically significantly more common in the DM (11.1%), AO (14.8%) and HTH (6.2%) groups compared with the AF+HT group (0.6%). A comparative assessment of risk factors (smoking and alcohol) did not show significant differences in prevalence in the groups (22-44%). An assessment of the levels of fibrosis and remodeling markers found a statistically significant increase in the level of galectin-3 in groups of patients with concomitant extracardiac diseases and an increase in the NT-proBNP level, relative to reference values in all groups except DTG.
Conclusion. Patients with AF in combination with HT and comorbid extracardiac diseases have a more rapid AF progression.

About the Authors

L. D. Khidirova
Novosibirsk State Medical University
Russian Federation

MD, PhD, Associate Professor, Chair of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine

Krasny prosp. 52, Novosibirsk, 630091 Russia



D. A. Yakhontov
Novosibirsk State Medical University
Russian Federation

MD, PhD, Professor, Chair of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine

Krasny prosp. 52, Novosibirsk, 630091 Russia



S. A. Zenin
Novosibirsk Regional Clinical Cardiology Dispensary
Russian Federation

MD, PhD, Head of Department of Surgical Treatment of Complex Cardiac Arrhythmias and Electrocardiostimulation

Zalesskogo ul. 6-8, Novosibirsk, 630047 Russia



M. N. Mamedov
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Professor, Head of Laboratory for Interdisciplinary Approach in the Prevention of Chronic Non-Communicable Diseases

Petroverigsky per. 10, Moscow, 101990 Russia



References

1. Shlyakhto E.V., Ezhov A.V., Koziolova N.A., et al. Clinical portrait of a patient with atrial fibrillation in the Russian Federation. global register data GLORIA AF. Russian Journal of Cardiology. 2017;(9):21-7(In Russ.) DOI:10.15829/1560-4071-2017-9-138-142.

2. Martsevich S.Yu., Navasardyan A.R., Kutishenko N.P. Experience in studying atrial fibrillation on the basis of a PROFIL register. Cardiovascular Therapy and Prevention. 2014;13(2):35-9 (In Russ.) DOI: 10.15829/1728-8800-2014-2-35-39.

3. Bustamante J.O., Rucnudin A., Sachs F. Stretch-activated channels in heart cells: relevance to cardiac hypertrophy. J Cardiovasc Pharmacol. 1991;17:110-3.

4. Chowdhury E.K., Owen A., Krum H., et al. Second Australian National Blood Pressure Study Management Committee. Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens. 2014;32(3):525-33. DOI:10.1097/hjh.0000000000000028.

5. Leonova E.I., Shehan G.G., Zadionchenko V.S., Bogatyrova K.M. Atrial fibrillation in patients with chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2014;10(3):328-33. (In Russ.) DOI:10.20996/1819-6446-2014-10-3-328-333.

6. Boytsov S.A., Loukyanov M.M., Yakushin C.C., et al. Cardiovascular diseases registry (RECVASA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatient - polyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44 50. (In Russ.)

7. Campos G., Fernández V., Fernández E., et al. Association of free fatty acids with the insulin-resistant state but not with central obesity in individuals from Venezuela. Invest Clin. 2010;51:115-26.

8. Tsareva Yu.O., Sokolov I.M., Aristarin M.A. Thyroid function and its biorhythmic changes in ischemic heart disease and atrial fibrillation. Modern Problems of Science and Education. 2015;1(1):121-31 (In Russ.)

9. Filatov Yu.I., Perfileva M.V., Chernov A.V. Features of the prevalence and structure of arrhythmias in patients with chronic obstructive pulmonary disease. Young Scientist. 2018;5:160-4.

10. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;1 2(1 0):1360-420. DOI:10.1093/europace/euq350.

11. Podzolkov V.I., Tarzimanova A.I. Current predictors of atrial fibrillation progression. Rational Pharmacotherapy in Cardiology. 2019;15(2):149-58 (In Russ.) DOI:10.20996/1819-6446-2019-15-2-149-158.

12. Chowdhury E.K., Owen A., Krum H., et al. Second Australian National Blood Pressure Study Management Committee. Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens. 2014;32(3):525-33. DOI:10.1097/hjh.0000000000000028.

13. Duntas L.H., Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96(2):269-81. DOI:10.1016/j.mcna.2012.01.012.

14. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122 (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122.

15. Lok D.J., Lok S.I., Bruggink-Andre de la Porte P.W., et al. Galectin-3is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103-10. DOI:10.1007/s10557-014-6520-2.

16. De Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725-73. DOI:10.1016/j.jacc.2009.11.040.

17. Sandhu R.K., Ezekowitz J., Andersson U., et al. The ''obesity paradox'' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37:2869-78. DOI:10.1093/eurheartj/ehw124.

18. Mitchell G.F., Vasan R.S. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297(7):709-15. DOI:10.1001/jama.297.7.709.

19. Hobbs F.R., Taylor C.J., Jan Geersing G. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol. 2016;23:460-73. DOI:10.1177/2047487315571890.

20. De Vos C.B., Breishardt J., Camm A.J. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythmcontrol therapy. Am Heart J. 2012;163:887-93. DOI:10.1016/j.ahj.2012.02.015.


For citation:


Khidirova L.D., Yakhontov D.A., Zenin S.A., Mamedov M.N. Features of Atrial Fibrillation in Patients with Arterial Hypertension and Extracardial Disorders. Rational Pharmacotherapy in Cardiology. 2019;15(3):368-373. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-3-368-373

Views: 105


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)